Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical class
|
| gptkbp:category |
psychedelic phenethylamines
|
| gptkbp:chemicalFormula |
2,5-dimethoxyphenethylamine core
|
| gptkbp:discoveredBy |
gptkb:Alexander_Shulgin
|
| gptkbp:durationOfEffects |
4-8 hours (varies by compound)
|
| gptkbp:effect |
empathy
euphoria hallucinations altered perception stimulation |
| gptkbp:firstDescribed |
1970s
|
| https://www.w3.org/2000/01/rdf-schema#label |
2C family
|
| gptkbp:legalStatus |
varies by country
|
| gptkbp:mainStreet |
2C drugs
2C's |
| gptkbp:mechanismOfAction |
serotonin receptor agonist
dopamine receptor activity (some members) norepinephrine receptor activity (some members) |
| gptkbp:mentionedIn |
gptkb:PiHKAL
|
| gptkbp:molecularFormulaPattern |
C10H15NO2 (varies by substitution)
|
| gptkbp:notableMember |
gptkb:2C-T-2
gptkb:2C-T-7 gptkb:2C-E gptkb:2C-T-21 gptkb:2C-T-4 gptkb:2C-B gptkb:2C-C gptkb:2C-D gptkb:2C-H gptkb:2C-I gptkb:2C-N gptkb:2C-P |
| gptkbp:psychoactive |
true
|
| gptkbp:regulates |
Class A in the United Kingdom (some members)
Schedule I in the United States (some members) controlled in Australia (some members) controlled in Canada (some members) |
| gptkbp:relatedTo |
gptkb:DOx_family
gptkb:NBOMe_family mescaline |
| gptkbp:riskFactor |
overdose
legal prosecution adverse psychological effects |
| gptkbp:routeOfAdministration |
oral
insufflation |
| gptkbp:subclassOf |
gptkb:phenethylamines
|
| gptkbp:toxicity |
varies by compound
|
| gptkbp:type |
gptkb:tablet
capsule powder |
| gptkbp:usedFor |
recreational purposes
psychedelic experiences |
| gptkbp:bfsParent |
gptkb:NBOH
|
| gptkbp:bfsLayer |
6
|